Price Alert

Exicure Inc. (XCUR)

NASDAQ: XCUR · Real-Time Price · USD

6.82

-0.03 (-0.44%)

At close: Aug 15, 2025, 2:29 PM

-0.44% (1D)

Bid	6.76
Market Cap	43.09M
Revenue (ttm)	n/a
Net Income (ttm)	-5.86M
EPS (ttm)	-3.86
PE Ratio (ttm)	-1.77
Forward PE	n/a
Analyst	n/a

Ask	7
Volume	17,425
Avg. Volume (20D)	116,724
Open	7.00
Previous Close	6.85
Day's Range	6.76 - 7.00
52-Week Range	1.44 - 36.00
Beta	3.68

About XCUR

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol XCUR

Website n/a

Full Company Profile

Why Price Moved

1 week ago

-3.37%

Exicure shares are trading higher after the compan... Unlock content with Pro Subscription

6 months ago

-15.07%

Exicure shares are trading higher after the company announced it entered into a share purchase agreement to acquire all of the issued and outstanding equities of GPCR Therapeutics.

News

1 week ago · fool.com

Exicure Posts Wider Loss in Fiscal Q2

1 week ago · businesswire.com

Exicure, Inc. Reports Second Quarter 2025 Financial Results

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. Reports Second Quarter 2025 Financial Results.

1 week ago · businesswire.com

Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements.

2 weeks ago · businesswire.com

Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients.